News
Market and company headlines
BIIBAll
Loading
06:00Today1 Story
08:00Yesterday1 Story
06:00Oct 231 Story
03:00-17:00Oct 222 Stories
Biogen +5% on BofA Price Target Hike Ahead of “Relatively Quiet” Q3
Key TakeawaysBiogen shares rose 5% today after BofA raised its price target to $244 from $219 and kept a Neutral rating. BofA’s new target is close to the $247 consensus target, which has climbed 43% over the past year as analysts try to keep up with the stock.
B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244
B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.
08:00-10:00Oct 212 Stories
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics advance late-stage drug pipelines, with key regulatory decisions and clinical trial results ahead.
05:00-08:00Oct 212 Stories
Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm
Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts. Read more on BIIB stock here.
TD Cowen Maintains Buy on Biogen, Raises Price Target to $250
TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $250.
05:00Oct 201 Story
03:00-08:00Oct 192 Stories
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
Two oral presentations to highlight new 76-week data showing sustained proteinuria reduction and continued eGFR stabilization with a consistent long-term safety profileAdditional presentations to highlight nephrologist perspectives on gaps in current care practices and limited treatment options for antibody-mediated rejection (AMR)Presentations on the role of felzartamab, an investigational anti-CD38 monoclonal antibody, in multiple immune-mediated kidney diseases will also be featured CAMBRIDGE
Biogen To Demonstrate Data, Additional Scientific Presentations From Its Nephrology Portfolio At American Society Of Nephrology Kidney Week
Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of
06:00-21:00Oct 162 Stories
A kidney transplant milestone has Wall Street excited about Biogen
JPMorgan strongly reset its price target on the company’s attractive 2027 pipeline catalysts.
Biogen-backed Estuary nabs $93M for kidney disease gene therapy
The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."
04:00Oct 161 Story
06:00Oct 131 Story
18:00-20:00Oct 122 Stories
Biogen (BIIB) Stock Is Up, What You Need To Know
Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neutral with a $300 price target, raised from $210.
Biogen (BIIB) Stock May Be 49% Below Fair Value As Lupus Data Loom
Biogen has bounced back on the market over the past year, and that kind of recovery puts fresh focus on a simple question for you as a shareholder or potential buyer: Is the current share price aligned with what the business may realistically produce in cash over time, based on its existing drugs and pipeline investments? Over the past 12 months Biogen has delivered a 58.6% share price gain, which raises the stakes on whether the recent momentum is fully grounded in its future cash...
15:00-18:00Oct 122 Stories
What Biogen (BIIB)'s 52-Week Litifilimab CLE Data Means For Shareholders
Biogen Inc. recently reported 52-week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, showing sustained improvements in skin disease activity and a generally well tolerated safety profile in patients who had not responded to or tolerated standard antimalarial therapies. The extended data, supported by the FDA’s Breakthrough Therapy Designation for litifilimab in CLE, reinforce its potential as a first-in-class, once-monthly therapy targeting BDCA2 on...
Biogen (BIIB) Could Be 5% Undervalued After 52 Week Lupus Data
Biogen (BIIB) is back in focus after releasing 52 week Phase 2 data for litifilimab in cutaneous lupus erythematosus, reporting sustained improvements in skin activity and a safety profile described as consistent with earlier studies. For investors, the litifilimab update comes after a solid run in the Biogen share price, with a 90 day share price return of 17.6% and a year-to-date share price gain of 26.9%. The 1 year total shareholder return of 56.0% contrasts with declines over the 3 and 5...
12:00-14:00Oct 122 Stories
Biogen Upgraded to Buy at J.P. Morgan. How the Stock Could Rise 28%.
Biogen stock is upgraded to Overweight from Neutral at J.P. Morgan ahead of a slate of data readouts for compelling pipeline candidates.
Biogen Stock Could Keep Gaining. A J.P. Morgan Upgrade Is Just the Beginning.
Biogen stock is upgraded to Overweight from Neutral at J.P. Morgan ahead of a slate of data readouts for compelling pipeline candidates.
06:00Oct 41 Story
07:00-12:00Oct 22 Stories
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and improvements in disease activity (28.8%; CLASI-70) than at week 24 (19.0% and 21.7%, respectively)Rapid onset: Participants that switched from placebo to litifilimab experienced improvements in skin disease activity in as early as four weeks -- consistent with results seen in participants who started
Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin; Litifilimab Seen To Be Generally Well Tolerated
Biogen Inc. (NASDAQ:BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). The updated
07:00Oct 11 Story
00:00Sep 291 Story
09:00Sep 281 Story
18:00Sep 251 Story
05:00-11:00Sep 232 Stories
How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data
Earlier this month, Eisai and Biogen secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer’s disease, while Biogen also published Phase 3 VALIANT adolescent subgroup data showing EMPAVELI improved proteinuria and stabilized kidney function in rare complement-mediated kidney disorders. Together, these updates highlight Biogen’s push to make complex therapies more accessible in real-world settings, potentially broadening treatment reach in both...
Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?
Biogen (BIIB) is back in focus after publishing adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases, a catalyst that gives investors fresh clinical context around the stock. For context, Biogen’s recent clinical and product news has landed against a backdrop of stronger trading action, with a 1-day share price return of 2.87% on the latest close at US$225.36 and a 90-day share price return of 12.91%. Investors are weighing kidney and Alzheimer’s updates...
00:00Sep 221 Story
11:00-13:00Sep 212 Stories
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Novo Nordisk shares plunge over 7% as new targets fail to reassure investors
Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...
00:00Sep 211 Story
12:00-17:00Sep 172 Stories
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based on VALIANT studyPublication follows a recent FDA label update to expand EMPAVELI’s indication to include reducing the loss of kidney function in patients 12 years and older, in addition to reducing proteinuria CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today ann
Biogen Announces Publication Of Phase 3 VALIANT Adolescent Subgroup Data In CJASN Demonstrating 75% Proteinuria Reduction For EMPAVELI In Rare Kidney Diseases
EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based on VALIANT
03:00Sep 171 Story
06:00-12:00Sep 162 Stories
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.
Is Biogen Stock Outperforming the S&P 500?
Biogen has outpaced the broader S&P 500 Index over the past year, and analysts remain reasonably upbeat about the stock’s prospects.
02:00Sep 161 Story
00:00-06:00Sep 152 Stories
Hummingbird Bioscience Appoints Dr. James Garner as President
Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Hummingbird Bioscience (“Hummingbird”), a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today announced the appointment of Dr. James Garner as President. Dr. Garner will join Hummingbird Bioscience’s leadership team and work alongside
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quart
07:00Sep 141 Story
11:00-13:00Sep 42 Stories
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
00:00Sep 41 Story
09:00-20:00Sep 32 Stories
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BEDFORD, Mass. & CAMBRIDGE, Mass., September 03, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. Drave
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $225 to $245.
00:00-08:00Sep 33 Stories
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligible patients using a pre-filled syringe or autoinjector, following a step-up initiation schedule. LEQEMBI IQLIK is described as the first anti-amyloid therapy with an approved subcutaneous initiation option that can be started outside an infusion...
Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment
Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the
23:00Sep 21 Story
03:00-09:00Sep 12 Stories
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BEDFORD, Mass. & CAMBRIDGE, Mass., September 01, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. The g
Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced